{"entity":{"id":"prexasertib","kind":"drug","name":"Prexasertib","aka":["ACR-368","LY2606368"],"tldr":"Prexasertib is an experimental small molecule from Acrivon Therapeutics, in phase 2 trials for endometrial cancer, platinum-resistant ovarian cancer and head and neck squamous cell carcinoma.","summary":"Prexasertib (ACR-368, LY2606368) is a small molecule from Acrivon Therapeutics, with Eli Lilly as licensor (originator. A selective inhibitor of the DNA damage response checkpoint kinases CHK1 and CHK2. Acrivon uses its OncoSignature test on a tumour biopsy to pick patients predicted to respond. Its furthest stage is phase 2, for endometrial cancer, platinum-resistant ovarian cancer and head and neck squamous cell carcinoma. ClinicalTrials.gov registers it in 2 studies linked below. Registrational-intent phase 2b in endometrial cancer; Acrivon plans to start a phase 3 confirmatory trial in the first half of 2027 (Q2 2026 results release, 12 August 2026). Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Acrivon Therapeutics: acrivon.com","url":"https://acrivon.com/pipeline/"},{"label":"Acrivon Therapeutics: acrivon.com","url":"https://acrivon.com/pipeline/"},{"label":"Acrivon Therapeutics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/acrv-ex99_1.htm"},{"label":"Acrivon Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06597565"},{"label":"ClinicalTrials.gov: trials of ACR-368","url":"https://clinicaltrials.gov/search?intr=ACR-368"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["endometrial","head-and-neck"],"sections":[],"technologies":[],"targets":["chek1","chek2"],"drugs":[],"companies":["acrivon-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05548296","nct06597565"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ACR-368","modality":"Small molecule","mechanism":"A selective inhibitor of the DNA damage response checkpoint kinases CHK1 and CHK2. Acrivon uses its OncoSignature test on a tumour biopsy to pick patients predicted to respond.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/prexasertib/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"target":[{"id":"chek1","kind":"target","name":"CHEK1","route":"/targets/chek1/"},{"id":"chek2","kind":"target","name":"CHEK2","route":"/targets/chek2/"}],"company":[{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","route":"/companies/acrivon-therapeutics/"}],"trial":[{"id":"nct05548296","kind":"trial","name":"A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma","route":"/trials/nct05548296/"},{"id":"nct06597565","kind":"trial","name":"A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC","route":"/trials/nct06597565/"}]}}